REBOOT Trial Finds Beta Blockers Fail 8,505 Uncomplicated Heart Attack Patients, Raising Risk for Women
Updated
Updated · ScienceDaily · May 25
REBOOT Trial Finds Beta Blockers Fail 8,505 Uncomplicated Heart Attack Patients, Raising Risk for Women
3 articles · Updated · ScienceDaily · May 25
8,505 patients in the REBOOT trial showed no significant drop in death, repeat heart attack or heart-failure hospitalization when beta blockers were added after uncomplicated heart attacks with preserved heart function.
109 hospitals in Spain and Italy followed patients for nearly 4 years, testing the drugs against modern care that already includes rapid artery reopening, statins and antiplatelet therapy.
Women with fully normal heart function faced a 2.7% higher absolute mortality risk over 3.7 years on beta blockers, while the same excess risk was not seen in men.
More than 80% of uncomplicated heart-attack patients are still discharged on beta blockers, so the findings could cut routine prescribing, side effects and pill burden.
Recent evidence has already questioned blanket use after myocardial infarction, with pooled data suggesting any benefit may be limited to patients with mildly reduced heart function.
Will millions of heart attack survivors soon be advised to stop taking their beta blockers?
Why might a standard heart attack drug now pose a greater danger to women than men?
Landmark REBOOT Trial: Routine Beta-Blockers After Heart Attack Offer No Benefit for Most, May Harm Women With Preserved Heart Function
Overview
The REBOOT Trial is a major international study that challenged over 40 years of standard practice by showing that beta-blockers, long considered essential after a heart attack, may not benefit most patients with preserved heart function. Despite being widely prescribed, the actual advantages of beta-blockers in modern cardiac care were unproven, and they can cause side effects like fatigue and low heart rate. The REBOOT Trial was specifically designed to answer whether these drugs are truly necessary for all patients, revealing that routine use should be reconsidered in light of new evidence.